1984
BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
Bakemeier R, Anderson J, Costello W, Rosner G, Horton J, Glick J, Hines J, Berard C, DeVita V. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study. Annals Of Internal Medicine 1984, 101: 447-56. PMID: 6089632, DOI: 10.7326/0003-4819-101-4-447.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBlood Cell CountCarmustineClinical Trials as TopicCombined Modality TherapyCyclophosphamideFemaleGastrointestinal DiseasesHematologic DiseasesHodgkin DiseaseHumansMaleMechlorethamineNeoplasm StagingPeripheral Nervous System DiseasesPrednisoneProcarbazineRandom AllocationVinblastineVincristineConceptsAdvanced Hodgkin's diseaseHodgkin's diseaseUntreated patientsEastern Cooperative Oncology Group studyDuration of complete remissionRandomized prospective studyTreatment of patientsMOPP regimenHematologic toxicityInduction chemotherapyComplete remissionChemotherapy regimensRemission rateNeurological toxicityProspective studyMOPPRemissionTherapeutic benefitChemotherapyPatientsInduction phaseDiseaseToxicityGroup studyDurationSecond malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience.
Tester W, Kinsella T, Waller B, Makuch R, Kelley P, Glatstein E, DeVita V. Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. Journal Of Clinical Oncology 1984, 2: 762-9. PMID: 6547479, DOI: 10.1200/jco.1984.2.7.762.Peer-Reviewed Original ResearchConceptsSecond malignant neoplasmsHodgkin's diseaseMalignant neoplasmsSolid tumorsNational Cancer Institute ExperienceChronic myeloid leukemiaCases of sarcomaRisk of leukemiaUntreated patientsPatient ageHodgkin's lymphomaMedical recordsInstitute experienceMyeloid leukemiaSimilar riskAge 40Treatment groupsPatientsGreater riskLeukemiaTen yearsDiseaseTumorsLymphomaPositive association
1983
Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.
Fisher R, DeVita V, Hubbard S, Longo D, Wesley R, Chabner B, Young R. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Annals Of Internal Medicine 1983, 98: 304-9. PMID: 6600902, DOI: 10.7326/0003-4819-98-3-304.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBlood PlateletsCyclophosphamideDoxorubicinDrug Administration ScheduleDrug Therapy, CombinationEtoposideFemaleHumansLeucovorinLeukopeniaLymphomaMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazineVincristineConceptsComplete remission rateDiffuse aggressive lymphomasMOPP chemotherapyRemission rateAggressive lymphomaDose-limiting toxicityRelapse-free survivalNew treatment programPhases of treatmentComplete remissionComplete respondersMedian durationMedian survivalUntreated patientsTumor responsePatient rateLate intensificationPatientsAdvanced stageChemotherapyTreatment programSurvivalLymphoma
1980
Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease.
Fisher R, DeVita V, Bostick F, Vanhaelen C, Howser D, Hubbard S, Young R. Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease. Annals Of Internal Medicine 1980, 92: 595-9. PMID: 6992672, DOI: 10.7326/0003-4819-92-5-595.Peer-Reviewed Original ResearchConceptsLong-term survivorsMitogen-induced lymphocyte proliferationPersistent immunologic abnormalitiesHodgkin's diseaseImmunologic abnormalitiesE rosettesLymphocyte proliferationAdvanced diffuse histiocytic lymphomaDepressed cellular immunityAdvanced Hodgkin's diseaseDisease-free intervalDiffuse histiocytic lymphomaB cell numbersNormal control subjectsComparable chemotherapyMOPP chemotherapyUntreated patientsCellular immunityControl subjectsHistiocytic lymphomaImmunologic studiesNormal rangeControl populationChemotherapyAbnormalities
1979
A comparison between combination chemotherapy and total body irradiation plus combination chemotherapy in non‐Hodgkin's lymphoma
Brereton H, Young R, Longo D, Kirkland L, Berard C, Jaffe E, Devita V, Johnson R. A comparison between combination chemotherapy and total body irradiation plus combination chemotherapy in non‐Hodgkin's lymphoma. Cancer 1979, 43: 2227-2231. PMID: 378350, DOI: 10.1002/1097-0142(197906)43:6<2227::aid-cncr2820430611>3.0.co;2-j.Peer-Reviewed Original Research
1977
Risk of new cancers in patients with Hodgkin's disease
Arseneau J, Canellos G, Johnson R, Devita V. Risk of new cancers in patients with Hodgkin's disease. Cancer 1977, 40: 1912-1916. PMID: 907993, DOI: 10.1002/1097-0142(197710)40:4+<1912::aid-cncr2820400823>3.0.co;2-d.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseAcute nonlymphocytic leukemiaNew cancersActive Hodgkin's diseaseLong-term complicationsSecond malignant tumorsReports of casesNational Cancer InstituteDirect cellular damageSynergistic carcinogenic effectPotential contributory factorsFurther immunosuppressionUntreated patientsImmunologic abnormalitiesTerm complicationsImproved survivalHD patientsImmunosuppressive factorsNonlymphocytic leukemiaMalignant diseaseMalignant tumorsCancer InstitutePatientsCytotoxic drugsTherapeutic interventionsAdvanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination.
Young R, Johnson R, Canellos G, Chabner B, Brereton H, Berard C, DeVita V. Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination. Journal Of The National Cancer Institute 1977, 61: 1153-9. PMID: 332349.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBlood PlateletsClinical Trials as TopicCyclophosphamideDrug Therapy, CombinationFemaleHumansLeukocytesLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMaleMiddle AgedNeoplasm StagingPrednisoneProcarbazineProspective StudiesRadiation DosageRadiation InjuriesRemission, SpontaneousTime FactorsVincristineConceptsHigher overall response rateCyclic combination chemotherapyOverall response rateCombination chemotherapyMedian followupResponse rateSimilar complete remission ratesRelapse-free survival rateComparison of chemotherapyMonths median followupComplete remission rateOverall median survivalDisease-free survivalTotal body irradiationNodular mixed lymphomaInduction regimenInduction therapyComplete remissionMedian survivalProspective trialRemission rateUntreated patientsMixed lymphomaMalignant lymphomaNodular lymphoma
1976
Pathological staging of 100 consecutive untreated patients with non‐Hodgkin's lymphomas. Extramedullary sites of disease
Lotz M, Chabner B, Devita V, Johnson R, Berard C. Pathological staging of 100 consecutive untreated patients with non‐Hodgkin's lymphomas. Extramedullary sites of disease. Cancer 1976, 37: 266-270. PMID: 1247961, DOI: 10.1002/1097-0142(197601)37:1<266::aid-cncr2820370136>3.0.co;2-z.Peer-Reviewed Original ResearchConceptsPathological stagingHodgkin's lymphomaNodular lymphomaHepatic biopsyDiffuse lymphomaFirst positive biopsyPercutaneous hepatic biopsyConsecutive untreated patientsBone marrow needle biopsyNegative spleensAbdominal involvementExploratory laparotomyUntreated patientsHepatic involvementWedge biopsyHistologic typeOverall incidenceRappaport classificationAbdominal diseasePositive biopsiesExtramedullary sitesNeedle biopsyUntreated casesPatientsBiopsy
1975
In vitro granulocyte production in patients with Hodgkin's disease and lymphocytic, histiocytic, and mixed lymphomas.
Bull J, DeVita V, Carbone P. In vitro granulocyte production in patients with Hodgkin's disease and lymphocytic, histiocytic, and mixed lymphomas. Blood 1975, 45: 833-42. PMID: 1125431, DOI: 10.1182/blood.v45.6.833.bloodjournal456833.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseMixed lymphomaUntreated patientsHistiocytic-lymphocytic lymphomasAdvanced Hodgkin's diseaseMOPP chemotherapyGranulocyte colony formationCombination chemotherapyMarrow culturesCFU-CIn vitro examinationLymphomaChemotherapyGranulocyte productionPatientsLong-term effectsAcute responseHodgkinColony formationDecreased numberDiseaseColony growthIn Vitro Granulocyte Production in Patients With Hodgkin’s Disease and Lymphocytic, Histiocytic, and Mixed Lymphomas
Bull J, DeVita V, Carbone P. In Vitro Granulocyte Production in Patients With Hodgkin’s Disease and Lymphocytic, Histiocytic, and Mixed Lymphomas. Blood 1975, 45: 833-842. DOI: 10.1182/blood.v45.6.833.833.Peer-Reviewed Original ResearchHodgkin's diseaseMixed lymphomaUntreated patientsHistiocytic-lymphocytic lymphomasAdvanced Hodgkin's diseaseMOPP chemotherapyGranulocyte colony formationCombination chemotherapyMarrow culturesCFU-CIn vitro examinationLymphomaChemotherapyGranulocyte productionPatientsLong-term effectsAcute responseHodgkinColony formationDecreased numberDiseaseColony growthPercutaneous liver biopsy, peritoneoscopy and laparotomy: an assessment of relative merits in the lymphomata.
Chabner B, Johnson R, Chretien P, Schein P, Young R, Canellos C, Hubbard S, Anderson T, Rosenoff S, DeVita V. Percutaneous liver biopsy, peritoneoscopy and laparotomy: an assessment of relative merits in the lymphomata. British Journal Of Cancer. Supplement 1975, 2: 242-7. PMID: 126693, PMCID: PMC2149568.Peer-Reviewed Original ResearchConceptsPercutaneous liver biopsyLiver biopsyLymphocytic lymphomaUntreated patientsHodgkin's lymphomaPercutaneous liver biopsy specimensStage IV diseaseConsecutive untreated patientsWedge liver biopsyLiver biopsy specimensLiver involvementPositive biopsiesBiopsy specimensPercutaneous biopsyLaparotomyPatientsBiopsyLymphomaPositive findingsTwo-thirdsFindingsDiseaseLiver
1974
Chemotherapy of advanced ovarian carcinoma: A prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide
Young R, Canellos G, Chabner B, Schein P, Hubbard S, DeVita V. Chemotherapy of advanced ovarian carcinoma: A prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide. Gynecologic Oncology 1974, 2: 489-497. PMID: 4376998, DOI: 10.1016/0090-8258(74)90059-6.Peer-Reviewed Original ResearchConceptsAdvanced ovarian carcinomaComplete remissionMedian durationOvarian carcinomaLong-term disease-free survivalTerm disease free survivalHigh-dose cyclophosphamideDisease-free survivalProspective Randomized ComparisonDose cyclophosphamideIntravenous cyclophosphamideIntensive regimenMelphalan therapyFree survivalInitial remissionMedian survivalUnacceptable toxicityUntreated patientsAgent therapyRandomized comparisonPresent studyHigh dosePhenylalanine mustardRemissionChemotherapyThrombocytosis in Chronic Granulocytic Leukemia: Incidence and Clinical Significance
Mason J, DeVita V, Canellos G. Thrombocytosis in Chronic Granulocytic Leukemia: Incidence and Clinical Significance. Blood 1974, 44: 483-487. PMID: 4528824, DOI: 10.1182/blood.v44.4.483.483.Peer-Reviewed Original ResearchConceptsChronic granulocytic leukemiaPlatelet countGranulocytic leukemiaClinical significanceOccurrence of thrombocytosisElevated platelet countThrombohemorrhagic complicationsUntreated patientsMedian durationShorter survivalBlastic crisisNormal countsPatientsSubsequent courseThrombocytosisLeukemiaCountEntire courseGroupCourseComplicationsClinicIncidenceDiagnosis
1973
Combination Chemotherapy and Survival in Advanced Hodgkin's Disease
Canellos G, Young R, Berard C, DeVita V. Combination Chemotherapy and Survival in Advanced Hodgkin's Disease. JAMA Internal Medicine 1973, 131: 388-390. PMID: 4569375, DOI: 10.1001/archinte.1973.00320090078008.Peer-Reviewed Original ResearchImmune Alterations in Hodgkin's Disease: Effect of Delayed Hypersensitivity and Lymphocyte Transformation on Course and Survival
Young R, Corder M, Berard C, DeVita V. Immune Alterations in Hodgkin's Disease: Effect of Delayed Hypersensitivity and Lymphocyte Transformation on Course and Survival. JAMA Internal Medicine 1973, 131: 446-454. DOI: 10.1001/archinte.1973.00320090136016.Peer-Reviewed Original ResearchHodgkin's diseaseLymphocyte transformationDelayed hypersensitivityFrequency of relapsesSkin test reactivityFive-year followSkin test antigensPeripheral leukocyte culturesRemission durationUntreated patientsImmune alterationsHistologic typeSkin testSystemic symptomsTest reactivityTest antigenLeukocyte culturesDiseaseHypersensitivitySurvivalDinitrochlorobenzeneCourseRelapseMumpsPatients
1972
Phytohemagglutinin-induced Lymphocyte Transformation: The Relationship to Prognosis of Hodgkin's Disease
Corder M, Young R, Brown R, DeVita V. Phytohemagglutinin-induced Lymphocyte Transformation: The Relationship to Prognosis of Hodgkin's Disease. Blood 1972, 39: 595-601. PMID: 5022714, DOI: 10.1182/blood.v39.5.595.595.Peer-Reviewed Original ResearchDelayed hypersensitivity in Hodgkin's disease A study of 103 untreated patients
Young R, Corder M, Haynes H, DeVita V. Delayed hypersensitivity in Hodgkin's disease A study of 103 untreated patients. The American Journal Of Medicine 1972, 52: 63-72. PMID: 5058359, DOI: 10.1016/0002-9343(72)90008-3.Peer-Reviewed Original ResearchConceptsSkin test reactivityPeripheral lymphocyte countTest reactivityHodgkin's diseaseLymphocyte countUntreated patientsPrognostic signSkin testAbsolute peripheral lymphocyte countLymphocyte-depleted Hodgkin's diseaseMean absolute lymphocyte countIncidence of anergyStage IV diseaseAbsolute lymphocyte countBad prognostic signDuration of remissionFrequency of relapsesTime of diagnosisStage of diseaseUseful prognostic signCutaneous anergyPeripheral lymphocytopeniaMixed cellularityMumps antigenNodular sclerosis
1970
Abnormalities of Tryptophan Metabolism and Plasma Pyridoxal Phosphate in Hodgkin's Disease
Chabner B, DeVita V, Livingston D, Oliverio V. Abnormalities of Tryptophan Metabolism and Plasma Pyridoxal Phosphate in Hodgkin's Disease. New England Journal Of Medicine 1970, 282: 838-843. PMID: 5418547, DOI: 10.1056/nejm197004092821504.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseUntreated patientsPlasma levelsPlasma pyridoxal phosphate levelsPlasma pyridoxal phosphatePyridoxal phosphate levelsAdvanced diseaseComplete remissionSymptomatic diseaseImmunosuppressive effectsAbnormal resultsPyridoxine deficiencyNormal limitsTryptophan metabolismPatientsDiseasePyridoxal phosphatePhosphate levelsDeficiencyL-tryptophanLittle evidenceMetabolismRemissionChemotherapyAnemia